Description
DCSZ11 is an investigational medication currently being studied in clinical trials for colorectal cancer. Specifically, it is being evaluated in patients with locally advanced rectal cancer that is mismatch repair proficient (pMMR), meaning it does not have a high number of mutations (microsatellite instability-stable or MSS). The trials are looking at combining DCSZ11 with standard treatments like radiation and chemotherapy (capecitabine and oxaliplatin) before surgery (neoadjuvant setting). The goal is to see if this combination is safe and effective in shrinking tumors or improving outcomes for these patients. It is important to note that DCSZ11 is not yet approved for use and is still in the research phase.
Mechanism of Action
The specific way DCSZ11 works is being investigated in clinical trials. It is being studied in combination with radiation and chemotherapy to treat locally advanced rectal cancer. The trials are focused on patients whose tumors are mismatch repair proficient (pMMR). The exact molecular target or mechanism of action is not yet fully defined but is being characterized during these studies.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.